Trial
NCT01123707
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborators
—
Condition
Major Depressive Disorder (MDD)
Intervention
Aripiprazole
Why stopped
The study was terminated early due to Sponsor decision; no safety issues.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-12-22